Liquid Biopsy and Epigenetic Signatures in AML, ALL, and CNS Tumors: Diagnostic and Monitoring Perspectives
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26157547 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Anne Aries und 2 weiteren Autor:innen. Beteiligte Einrichtung: Institut de Recherche en Hématologie et Transplantation (IRHT), Hôpital du Hasenrain, 87 Avenue d'Altkirch, 68100 Mulhouse, France. Hauptthemen laut MEDLINE: Epigenesis, Genetic, Central Nervous System Neoplasms, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Le Fonds Européen de Développement Régional (FEDER), Région Grand Est, Mulhouse Alsace Agglomération and Fondation Lalance.
Abstract (Originalsprache)
To deliver the most effective cancer treatment, clinicians require rapid and accurate diagnoses that delineate tumor type, stage, and prognosis. Consequently, minimizing the need for repetitive and invasive procedures like biopsies and myelograms, along with their associated risks, is a critical challenge. Non-invasive monitoring offers a promising avenue for tumor detection, screening, and prognostication. While the identification of oncogenes and biomarkers from circulating tumor cells or tissue biopsies is currently standard practice for cancer diagnosis and classification, accumulating evidence underscores the significant role of epigenetics in regulating stem cell fate, including proliferation, self-renewal, and malignant transformation. This highlights the importance of analyzing the methylome, exosomes, and circulating RNA for detecting cellular transformation. The development of diagnostic assays that integrate liquid biopsies with epigenetic analysis holds immense potential for revolutionizing tumor management by enabling rapid, non-invasive diagnosis, real-time monitoring, and personalized treatment decisions. This review covers current studies exploring the use of epigenetic regulation, specifically the methylome and circulating RNA, as diagnostic tools derived from liquid biopsies. This approach shows promise in facilitating the differentiation between primary central nervous system lymphoma and other central nervous system tumors and may enable the detection and monitoring of acute myeloid/lymphoid leukemia. We also discuss the current limitations hindering the rapid clinical translation of these technologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institut de Recherche en Hématologie et Transplantation (IRHT), Hôpital du Hasenrain, 87 Avenue d'Altkirch, 68100 Mulhouse, France.
- Laboratoire d'Hématologie, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, Hôpital E. Muller, 20 Avenue de Dr. Laennec, 68100 Mulhouse, France.
ORCID-Profile: Anne Aries, Bernard Drénou, Rachid Lahlil
Förderung
- Le Fonds Européen de Développement Régional (FEDER)
- Région Grand Est, Mulhouse Alsace Agglomération and Fondation Lalance
Zitieren
APA
Aries, A., Drénou, B., & Lahlil, R. (2025). Liquid Biopsy and Epigenetic Signatures in AML, ALL, and CNS Tumors: Diagnostic and Monitoring Perspectives. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26157547
Vancouver
Aries A, Drénou B, Lahlil R. Liquid Biopsy and Epigenetic Signatures in AML, ALL, and CNS Tumors: Diagnostic and Monitoring Perspectives. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26157547
BibTeX
@article{Aries2025,
author = {Aries, Anne and Drénou, Bernard and Lahlil, Rachid},
title = {Liquid Biopsy and Epigenetic Signatures in AML, ALL, and CNS Tumors: Diagnostic and Monitoring Perspectives},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26157547}
}
EUVIMED